AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11244441
Drug: Meningococcal polysaccharide
RxNorm normalized name: meningococcal polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal polysaccharide (Men PS) vaccine, administered 20 months after BMT (late group; 22 patients)
Trial: 11244441
Drug: Meningococcal polysaccharide
RxNorm normalized name: meningococcal polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal polysaccharide (Men PS) vaccine, both early and late groups
Trial: 9855434
Drug: Three-component acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-component acellular vaccine (3-5-12 schedule)
Trial: 9855434
Drug: Five-component vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-component vaccine (3-5-12 schedule)
Trial: 9855434
Drug: Whole-cell vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-cell vaccine (3-5-12 schedule)
Trial: 9855434
Drug: Multicomponent acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent acellular vaccine (2-4-6 schedule)
Trial: 9855434
Drug: Delayed third
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed third dose (both schedules)
Trial: 31481010
Drug: Transforaminal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal epidural injection (TEI) with lidocaine and methylprednisolone acetate for L3 and below, and lidocaine with dexamethasone above L3.
Trial: 31481010
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral pain medication.
Trial: 24995271
Drug: Levofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (500 mg), amoxicillin/clavulanate (875 mg/125 mg), and rabeprazole (20 mg) twice per day (LAcR)
Trial: 24995271
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg), amoxicillin (1000 mg), and rabeprazole (20 mg) twice per day (CAR)
Trial: 22766314
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m² intravenously day 1 with vitamin B12, folic acid, and dexamethasone
Trial: 22766314
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² intravenously day 1 with dexamethasone
Trial: 18849664
Drug: DTwP/HB vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTwP/HB vaccine (Q‐Vac) administered alone (Group A)
Trial: 18849664
Drug: DTwP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTwP and HB vaccines at separate sites (Group B)
Trial: 18849664
Drug: DTPw/HB vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPw/HB vaccine (Tritanrix HB) (Group C)
Trial: 17719471
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg for 6 weeks
Trial: 17719471
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg for 6 weeks
Trial: 3319721
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of grenz ray treatment and topical steroid
Trial: 3319721
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid alone
Trial: 30630789
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of cefmetazole and traditional excision
Trial: 24368363
Drug: Intensive physiotherapy
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive physiotherapy (usual care plus two additional 30-minute treatments each day)
Trial: 24368363
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (daily physiotherapy treatment, approximately 30 minutes)
Trial: 18235122
Drug: Standard-dose imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose imatinib (400 mg daily)
Trial: 18235122
Drug: Standard-dose imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose imatinib (400 mg daily) followed by high-dose imatinib (400 mg twice daily) after progression
Trial: 15653971
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP), 1,000 microg/d, then reduced to 200 microg/d (group 1)
Trial: 15653971
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of FP, 200 microg/d (group 2)
Trial: 12608491
Drug: Alcoholic beer
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcoholic beer (8.5%) administered to reach a blood alcohol concentration of 40 mg/dl
Trial: 10440421
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg once daily for 10 days
Trial: 1316060
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oral lomefloxacin 2-6 hours before surgery
Trial: 1316060
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g parenteral cefuroxime 30-90 minutes before surgery
Trial: 1316060
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oral lomefloxacin
Trial: 1316060
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g parenteral cefuroxime
Trial: 3904259
Drug: Live, attenuated
RxNorm normalized name: Ebola Zaire vaccine (live, attenuated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live, attenuated cold‐adapted influenza A vaccines (H1N1 and H3N2)
Trial: 26872892
Drug: Ixazomib administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib administered after a high-fat meal
Trial: 26872892
Drug: Ixazomib administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib administered in fasted state
Trial: 23315999
Drug: Brief eclectic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief eclectic psychotherapy for PTSD (successful treatment group, n = 10)
Trial: 23315999
Drug: Brief eclectic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief eclectic psychotherapy for PTSD (unsuccessful treatment group, n = 10)
Trial: 17938943
Drug: Oral chlormadinone
RxNorm normalized name: chlormadinone
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chlormadinone acetate
Trial: 16669976
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg/d (FA-5)
Trial: 16669976
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 15 mg/d (FA-15)
Trial: 12796671
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg fluoxetine once weekly
Trial: 11370345
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg aqueous extract powder in 10 mL distilled water
Trial: 11370345
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL distilled water (control)
Trial: 8841891
Drug: Odontoson M
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odontoson M plus an ionized irrigant solution
Trial: 3675133
Drug: 0.75 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mL/kg of ethanol
Trial: 3675133
Drug: 1.1 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1 mL/kg of ethanol
Trial: 30944165
Drug: Concurrent focal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent focal noninvasive transcranial magnetic stimulation and electroencephalography
Trial: 30944165
Drug: Psychotherapy (best-validated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy (best-validated treatment for PTSD)
Trial: 27631861
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy with reflective practice by therapists
Trial: 27631861
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy without consideration of group dynamics
Trial: 24983187
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg spironolactone (MRB group)
Trial: 24983187
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ramipril (RASB group)
Trial: 18547863
Drug: No recovery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No recovery treatment (control)
Trial: 12461195
Drug: DISH administered
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DISH administered by research nurses
Trial: 7762527
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of iodized oil A (490 mg I)
Trial: 7762527
Drug: Split dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split dose of iodized oil A (2 x 245 mg I)
Trial: 7762527
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of iodized oil B (675 mg I)
Trial: 7762527
Drug: Divided dose
RxNorm normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided dose of oil A (2 x 245 mg I)
Trial: 2065322
Drug: Melanoma vaccine
RxNorm normalized name: melanoma vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melanoma vaccine plus cyclophosphamide (300 mg/m2 i.v. 3 days prior to each vaccine immunization)
Trial: 2065322
Drug: Melanoma vaccine
RxNorm normalized name: melanoma vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melanoma vaccine alone
Trial: 2065322
Drug: Melanoma vaccine
RxNorm normalized name: melanoma vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melanoma vaccine plus cyclophosphamide
Trial: 6634945
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment at 0.5 W/cm2
Trial: 6634945
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment at 1.0 W/cm2
Trial: 6634945
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment at 1.5 W/cm2
Trial: 6634945
Drug: Placebo ultrasound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ultrasound treatment at 0.0 W/cm2
Trial: 24105031
Drug: U‐cas supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U‐cas supplementation at 180 g/kg DM in feed block (FB)
Trial: 24105031
Drug: U‐cas supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U‐cas supplementation at 180 g/kg DM in FB
Trial: 24105031
Drug: U‐cas supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U‐cas supplementation at 150 g/kg DM in FB
Trial: 24105031
Drug: U‐cas supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U‐cas supplementation at 120 g/kg DM in FB
Trial: 24105031
Drug: U‐cas supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U‐cas supplementation at 0 g/kg DM in FB
Trial: 11845362
Drug: Early PDL
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early PDL therapy for capillary haemangiomas
Trial: 11845362
Drug: PDL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDL treatment for mixed haemangiomas
Trial: 2171853
Drug: Protein-rich meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-rich meal (50 g of bovine serum albumin added)
Trial: 7274405
Drug: time-limited therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: time-limited therapy of 6 sessions within 8 weeks
Trial: 7274405
Drug: time-limited therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: time-limited therapy of 12 sessions within 16 weeks
Trial: 7274405
Drug: time-unlimited therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: time-unlimited therapy
Trial: 30422243
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg every 2 weeks plus dacarbazine-matched placebo every 3 weeks)
Trial: 30422243
Drug: Dacarbazine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacarbazine (1000 mg/m2 every 3 weeks plus nivolumab-matched placebo every 2 weeks)
Trial: 28954982
Drug: Intramuscle injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscle injection of testosterone enanthate
Trial: 25209610
Drug: Trimethoprim/sulfamethoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim/sulfamethoxazole (160 mg/800 mg three times daily) plus rifampicin (600 mg once a day)
Trial: 25209610
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg twice a day)
Trial: 21257057
Drug: GLP-2 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-2 (50 μg/kg of body weight of bovine GLP-2 in BSA) given subcutaneously every 12h for 10 days
Trial: 21257057
Drug: GLP-2 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-2 (50 μg/kg of body weight of bovine GLP-2 in BSA)
Trial: 17704418
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy regimens (including cyclophosphamide, doxorubicin, fluorouracil, and paclitaxel)
Trial: 15221881
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training with creatine supplementation (5 g/day)
Trial: 11848236
Drug: Topical lignocaine/prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lignocaine/prilocaine
Trial: 27614164
Drug: No local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No local treatment (Control)
Trial: 9576390
Drug: RRV‐TV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRV‐TV vaccine (titer 4 x 10(5) plaque‐forming units)
Trial: 27142710
Drug: secukinumab 10
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: secukinumab 10 mg/kg
Trial: 21908446
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of 250 mg acetylsalicylic acid (ASA) + 200 mg paracetamol + 50 mg caffeine (Thomapyrin)
Trial: 11084060
Drug: Sirolimus (SRL)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus (SRL) 5‐ to 10‐mg load, 1 to 4 mg/d
Trial: 11084060
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) therapy
Trial: 1348159
Drug: Sulfasalazine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (4 g daily)
Trial: 30056410
Drug: Instrumental Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instrumental Group (self-treatment using an Occipivot cushion)
Trial: 24778002
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative therapy (OMTh) + conventional care
Trial: 20190350
Drug: 9% CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9% CHO solution
Trial: 12443833
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens 0.625 mg/day (ERT)
Trial: 12443833
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) with 5 mg/day continuous medroxyprogesterone
Trial: 8562470
Drug: slow-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: slow-release verapamil 240 mg once daily
Trial: 8562470
Drug: captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: captopril 25 mg daily (for nonresponders)
Trial: 2292349
Drug: Miglitol 100
RxNorm normalized name: miglitol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol 100 mg t.i.d. for 8 weeks
Trial: 9675626
Drug: Tramadol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (100 mg/2 mL)
Trial: 9675626
Drug: Pentazocine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (30 mg/mL)
Trial: 2572618
Drug: Midaglizole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midaglizole (200 mg)
Trial: 28185899
Drug: Lurasidone adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone adjunctive therapy (20-80 mg/day) for 6 weeks
Trial: 25305567
Drug: Coad (MenACWY‐TT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coad (MenACWY‐TT co-administered with DTaP)
Trial: 23566694
Drug: Systemic enzyme
RxNorm normalized name: alpha-D-galactosidase enzyme Chewable Tablet [Beano]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic enzyme therapy (twice-daily dose for 5 days starting from the first postoperative day)
Trial: 21285229
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron supplementation with 50 mg elemental iron for 14 weeks
Trial: 19125084
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with GaAlAs, wavelength 830 nm, power 100 mW, dose 4 J/cm, for 5 days
Trial: 16633139
Drug: Reboxetine 8‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 8‐10 mg per day
Trial: 16633139
Drug: Citalopram 20‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20‐40 mg per day
Trial: 8106898
Drug: Thrombolytic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic and anti-platelet therapy
Trial: 3605188
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of NPH and tolazamide
Trial: 23361101
Drug: Ephedra-free dietary
RxNorm normalized name: Ephedra sinica root
DrugBank: Ephedra sinica root (DB01363)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedra-free dietary supplements (four types), ingested three times daily for 3 days
Trial: 23361101
Drug: Ephedra-free dietary
RxNorm normalized name: Ephedra sinica root
DrugBank: Ephedra sinica root (DB01363)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedra-free dietary supplements (four types)
Trial: 23361101
Drug: Ephedra-free dietary
RxNorm normalized name: Ephedra sinica root
DrugBank: Ephedra sinica root (DB01363)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedra-free dietary supplements (two types)
Trial: 23361101
Drug: Ephedra-free dietary
RxNorm normalized name: Ephedra sinica root
DrugBank: Ephedra sinica root (DB01363)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedra-free dietary supplements
Trial: 18445111
Drug: Alcohol (male:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (male: 0.6 g/kg, female: 0.5 g/kg)
Trial: 17135158
Drug: Dysmo-off (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dysmo-off (5 g twice daily for 4 days, one day prior to and three days after menstruation)
Trial: 17135158
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (50 mg twice daily for 4 days, one day prior to and three days after menstruation)
Trial: 10742724
Drug: Indinavir alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir alone (800 mg q8h)
Trial: 10742724
Drug: Zidovudine alone
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine alone (200 mg q8h)
Trial: 8650247
Drug: Combined use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined use of other agents along with vitamin D
Trial: 6352611
Drug: 1-g intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-g intramuscular ceftazidime
Trial: 6352611
Drug: 2-g intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-g intramuscular ceftazidime (twice or thrice daily)
Trial: 26039494
Drug: Animal-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal-assisted therapy
Trial: 30204523
Drug: Higher-intensity taper
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-intensity taper (5.9% increase in intensity)
Trial: 30204523
Drug: Lower-intensity taper
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-intensity taper (8.5% decrease in intensity)
Trial: 18059577
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.1 g.kg(‐1).d(‐1))